Skip to main content
SpringerLink
Log in

A 100mg daily dose of micafungin delivers similar outcomes for patients with candidaemia as a 150mg dose, at lower costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Marfo K, Guo Y.Pharmacoeconomic analysis of micafungin (Mycamine) 100 mg and 150 mg daily in the treatment of candidemia. P and T 34: 196-199, No. 4, Apr 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A 100mg daily dose of micafungin delivers similar outcomes for patients with candidaemia as a 150mg dose, at lower costs. Pharmacoecon. Outcomes News 581, 8 (2009). https://doi.org/10.2165/00151234-200905810-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905810-00023

Keywords

Search

Navigation